Evidence map›Paper›PMID 40343010›Full record

ArticleCrohn's & colitis 3602025

Questionnaire Survey of Japanese Patients With Inflammatory Bowel Disease and Physicians on Shared Decision-Making in Advanced Therapy: A Web-Based PAIR Survey.

Fumihito Hirai, Takayuki Matsumoto, Keita Imai, Yuki Goda, Yuki Fujimitsu, Toshifumi Kajioka, Masami Oiwa, Tomoki Honjo, Masaaki Higashikawa, Masato Ueno

Abstract read
In one paragraph

Article in Crohn's & colitis 360, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fumihito HiraiDepartment of Gastroenterology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-5493-5675
Takayuki MatsumotoDivision of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.ORCID https://orcid.org/0000-0001-9786-3854
Keita ImaiDepartment of IBD Strategy, EA Pharma Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0000-7472-6160
Yuki GodaDepartment of IBD Strategy, EA Pharma Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0001-0227-115X
Yuki FujimitsuDepartment of IBD Strategy, EA Pharma Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0005-6207-4843
Toshifumi KajiokaDepartment of IBD Strategy, EA Pharma Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0004-3520-852X
Masami OiwaDepartment of IBD Strategy, EA Pharma Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0004-2562-3308
Tomoki HonjoDepartment of IBD Strategy, EA Pharma Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0007-3784-3203
Masaaki HigashikawaDepartment of Pharmaceutical Development, Development Promotion & Data Science Group, EA Pharma Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0003-3357-7412
Masato UenoDepartment of IBD Strategy, EA Pharma Co., Ltd., Tokyo, Japan.ORCID https://orcid.org/0009-0007-2410-1032

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: With the recent increase in available treatment options for inflammatory bowel disease (IBD), shared decision-making has gained considerable importance. To address potential disparities in patient and physician priorities, we conducted a survey to clarify these perspectives. Methods: Patients with IBD and physicians treating IBD were asked to complete an online questionnaire focused on key factors influencing drug selection and preferred drug administration methods. Results: Responses were obtained from 400 patients (327 with ulcerative colitis and 73 with Crohn's disease) and 155 physicians. Among the factors in drug selection, physicians assigned significantly higher importance scores for experience with the drug than did patients. The expected time to onset of drug effects was significantly different between patients and physicians. Regarding preferences for drug administration method, patients and physicians assigned the highest acceptability scores for once-daily oral administration. For intravenous and subcutaneous routes, patients' scores were significantly lower than those of physicians' scores. Notably, 86.0% of patients and 62.0% of physicians preferred oral administration as the most preferred method. However, preferences varied based on treatment experience: 34.7% of patients with prior experience with subcutaneous injection preferred this method. Conclusions: Patients and physicians generally shared similar priorities for drug selection; however, physicians emphasized their experience with the drug over patient preferences. Although the number of patients with prior treatment experience preferred intravenous or subcutaneous injections, oral formulations remained the preferred choice for both patients and physicians.

Indexed as

Crohn’s diseaseinflammatory bowel diseasepreferenceshared decision-makingulcerative colitis

Identifiers

PMID40343010
PMCPMC12059213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.